Intest Res.  2017 Jul;15(3):318-327. 10.5217/ir.2017.15.3.318.

Treatment and outcomes: medical and surgical treatment for intestinal Behçet's disease

• Hisamatsu
• Hayashida

• KMID: 2382375
• DOI: http://doi.org/10.5217/ir.2017.15.3.318

Abstract

Behçet's disease (BD) is a chronic relapsing disease involving multiple organ systems. BD is characterized clinically by oral and genital aphthae, cutaneous lesions, and ophthalmological, neurological, and/or gastrointestinal manifestations. It is widely recognized that the presence of intestinal lesions may be a poor prognostic factor in intestinal BD, increasing the risk of surgery and decreasing the quality of life. Despite this, the management of intestinal BD has not been standardized. Empirical therapies including 5-aminosalicylic acid and corticosteroids have been used anecdotally to treat intestinal BD, but recent studies have provided evidence for the efficacy of anti-tumor necrosis factor α monoclonal antibodies. The development of agents targeting tumor necrosis factor α continues, it seems likely that they will change the therapeutic strategy and clinical outcomes of intestinal BD and inflammatory bowel disease. Monitoring disease activity such as endoscopic evaluation will become more important to obtain better outcomes. Here, we review current and future perspectives in the treatment and outcomes of intestinal BD.

Keyword

Intestinal Behçet's disease; Anti-TNF-α mAb; Mucosal healing

MeSH Terms

Adrenal Cortex Hormones
Antibodies, Monoclonal
Inflammatory Bowel Diseases
Mesalamine
Necrosis
Quality of Life
Stomatitis, Aphthous
Tumor Necrosis Factor-alpha
Adrenal Cortex Hormones
Antibodies, Monoclonal
Mesalamine
Tumor Necrosis Factor-alpha

Reference

1. Behçet H. Über rezidivierende, aphthöse, durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wochenschr. 1937; 105:1152–1157.

2. Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol. 2012; 46:e38–e45. PMID: 22298088.

3. Hatemi I, Esatoglu SN, Hatemi G, Erzin Y, Yazici H, Celik AF. Characteristics, treatment, and long-term outcome of gastrointestinal involvement in Behcet's syndrome: a strobe-compliant observational study from a dedicated multidisciplinary center. Medicine (Baltimore). 2016; 95:e3348. PMID: 27100417.

4. Sonta T, Araki Y, Koubokawa M, et al. The beneficial effect of mesalazine on esophageal ulcers in intestinal Behcet's disease. J Clin Gastroenterol. 2000; 30:195–199. PMID: 10730926.

5. Hisamatsu T, Ueno F, Matsumoto T, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFalpha monoclonal antibodies. J Gastroenterol. 2014; 49:156–162. PMID: 23955155.

6. Nakase H, Okazaki K, Kawanami C, et al. Therapeutic effects on intestinal Behçet's disease of an intravenous drug delivery system using dexamethasone incorporated in lipid emulsion. J Gastroenterol Hepatol. 2001; 16:1306–1308. PMID: 11903753.

7. Toda K, Shiratori Y, Yasuda M, et al. Therapeutic effect of intraarterial prednisolone injection in severe intestinal Behçet's disease. J Gastroenterol. 2002; 37:844–848. PMID: 12424569.

8. Yasuo M, Miyabayashi H, Okano T, Aoki H, Ichikawa K, Hirose Y. Successful treatment with corticosteroid in a case of Behçet's syndrome with multiple esophageal ulcerations. Intern Med. 2003; 42:696–699. PMID: 12924494.

9. Cheon JH, Kim WH. An update on the diagnosis, treatment, and prognosis of intestinal Behçet's disease. Curr Opin Rheumatol. 2015; 27:24–31. PMID: 25405821.

10. Skef W, Hamilton MJ, Arayssi T. Gastrointestinal Behçet's disease: a review. World J Gastroenterol. 2015; 21:3801–3812. PMID: 25852265.

11. Hisamatsu T, Naganuma M, Matsuoka K, Kanai T. Diagnosis and management of intestinal Behçet's disease. Clin J Gastroenterol. 2014; 7:205–212. PMID: 24883128.

12. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med. 1999; 341:1284–1291. PMID: 10528040.

13. Kobayashi K, Ueno F, Bito S, et al. Development of consensus statements for the diagnosis and management of intestinal Behçet's disease using a modified Delphi approach. J Gastroenterol. 2007; 42:737–745. PMID: 17876543.

14. Grigg EL, Kane S, Katz S. Mimicry and deception in inflammatory bowel disease and intestinal Behçet disease. Gastroenterol Hepatol (N Y). 2012; 8:103–112. PMID: 22485077.

15. Saleh Z, Arayssi T. Update on the therapy of Behçet disease. Ther Adv Chronic Dis. 2014; 5:112–134. PMID: 24790727.

16. Park JJ, Cheon JH, Moon CM, et al. Long-term clinical outcomes after the first course of corticosteroid therapy in patients with moderate to severe intestinal Behget's disease. Gastroenterology. 2010; 138:S698–S699.

17. Kimura Y, Asako K, Kikuchi H, Kono H. Characteristics of patients with intestinal Behçet's disease requiring treatment with immunosuppressants or anti-TNFalpha antibody. Mod Rheumatol. 2016; 26:132–137. PMID: 26025434.

18. Takada Y, Saigenji K. Is intestinal Behçet's disease in fact an enterocolitis or an ulcer disease, and is steroid treatment useful or harmful? J Gastroenterol. 2003; 38:1015–1016. PMID: 14614614.

19. Takada Y, Fujita Y, Igarashi M, et al. Intestinal Behçet's disease: pathognomonic changes in intramucosal lymphoid tissues and effect of a “rest cure” on intestinal lesions. J Gastroenterol. 1997; 32:598–604. PMID: 9349984.

20. Jung YS, Cheon JH, Hong SP, Kim TI, Kim WH. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease. Inflamm Bowel Dis. 2012; 18:750–757. PMID: 21618352.

21. Lee HW, Cheon JH, Lee HJ, et al. Postoperative effects of thiopurines in patients with intestinal Behçet's disease. Dig Dis Sci. 2015; 60:3721–3727. PMID: 26199149.

22. Choi IJ, Kim JS, Cha SD, et al. Long-term clinical course and prognostic factors in intestinal Behçet's disease. Dis Colon Rectum. 2000; 43:692–700. PMID: 10826433.

23. Park MS, Kim DH, Kim DH, et al. Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance. Dig Dis Sci. 2015; 60:195–204. PMID: 25239495.

24. Iwata S, Saito K, Yamaoka K, et al. Efficacy of combination therapy of anti-TNF-alpha antibody infliximab and methotrexate in refractory entero-Behçet's disease. Mod Rheumatol. 2011; 21:184–191. PMID: 21052764.

25. Matsumura K, Nakase H, Chiba T. Efficacy of oral tacrolimus on intestinal Behcet's disease. Inflamm Bowel Dis. 2010; 16:188–189. PMID: 19504615.

26. Felipez LM, Gokhale R, Tierney MP, Kirschner BS. Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. J Pediatr Gastroenterol Nutr. 2012; 54:28–33. PMID: 21681114.

27. Akobeng AK, Stokkers PC. Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009; (2):CD007351. DOI: 10.1002/14651858.CD007351.pub2. PMID: 19370685.

28. Srinivasan R, Akobeng AK. Thalidomide and thalidomide analogues for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2009; (2):CD007350. DOI: 10.1002/14651858.CD007350.pub2. PMID: 19370684.

29. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut. 2001; 49:725–728. PMID: 11600479.

30. Terrin G, Borrelli O, Di Nardo G, Pacchiarotti C, Cucchiara S. A child with aphthae and diarrhoea. Lancet. 2002; 359:316. PMID: 11830199.

31. Kari JA, Shah V, Dillon MJ. Behçet's disease in UK children: clinical features and treatment including thalidomide. Rheumatology (Oxford). 2001; 40:933–938. PMID: 11511764.

32. Sayarlioglu M, Kotan MC, Topcu N, Bayram I, Arslanturk H, Gul A. Treatment of recurrent perforating intestinal ulcers with thalidomide in Behçet's disease. Ann Pharmacother. 2004; 38:808–811. PMID: 15010523.

33. Yasui K, Uchida N, Akazawa Y, et al. Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease. Inflamm Bowel Dis. 2008; 14:396–400. PMID: 17973303.

34. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology. 2001; 120:995–999. PMID: 11231954.

35. Kram MT, May LD, Goodman S, Molinas S. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum. 2003; 46:118–121. PMID: 12544532.

36. Lee JH, Kim TN, Choi ST, et al. Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab). Korean J Intern Med. 2007; 22:24–27. PMID: 17427642.

37. Ugras M, Ertem D, Celikel C, Pehlivanoglu E. Infliximab as an alternative treatment for Behçet disease when other therapies fail. J Pediatr Gastroenterol Nutr. 2008; 46:212–215. PMID: 18223383.

38. Ariyachaipanich A, Berkelhammer C, Nicola H. Intestinal Behçet's disease: maintenance of remission with adalimumab monotherapy. Inflamm Bowel Dis. 2009; 15:1769–1771. PMID: 19177427.

39. Naganuma M, Sakuraba A, Hisamatsu T, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. Inflamm Bowel Dis. 2008; 14:1259–1264. PMID: 18393375.

40. Maruyama Y, Hisamatsu T, Matsuoka K, et al. A case of intestinal Behçet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years. Intern Med. 2012; 51:2125–2129. PMID: 22892489.

41. Byeon JS, Choi EK, Heo NY, et al. Antitumor necrosis factoralpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case. Dis Colon Rectum. 2007; 50:672–676. PMID: 17216141.

42. Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Behçet's disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. 2013; 19:1833–1838. PMID: 23702810.

43. Kinoshita H, Kunisaki R, Yamamoto H, et al. Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication. Intern Med. 2013; 52:1855–1862. PMID: 23994973.

44. Tanida S, Inoue N, Kobayashi K, et al. Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease. Clin Gastroenterol Hepatol. 2015; 13:940–948.e3. PMID: 25245624.

45. Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore). 2016; 95:e3863. DOI: 10.1097/MD.0000000000003863. PMID: 27310969.

46. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008; 134:1861–1868. PMID: 18440315.

47. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut. 2009; 58:492–500. PMID: 18832518.

48. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362:1383–1395. PMID: 20393175.

49. Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013; 145:1464–1478. 1478.e1–1478.e5. PMID: 24267475.

50. Matsumoto T, Motoya S, Watanabe K, et al. Adalimumab monotherapy and a combination with azathioprine for Crohn's disease: a prospective, randomized trial. J Crohns Colitis. 2016; 10:1259–1266. PMID: 27566367.

51. Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep. 2013; 15:315. PMID: 23354742.

52. Lee HJ, Kim YN, Jang HW, et al. Correlations between endoscopic and clinical disease activity indices in intestinal Behcet's disease. World J Gastroenterol. 2012; 18:5771–5778. PMID: 23155319.

53. Yim SM, Kim DH, Lee HJ, et al. Mucosal healing predicts the long-term prognosis of intestinal Behçet's disease. Dig Dis Sci. 2014; 59:2529–2535. PMID: 24838499.

54. Naganuma M, Iwao Y, Inoue N, et al. Analysis of clinical course and long-term prognosis of surgical and nonsurgical patients with intestinal Behçet's disease. Am J Gastroenterol. 2000; 95:2848–2851. PMID: 11051358.

55. Jung YS, Cheon JH, Park SJ, Hong SP, Kim TI, Kim WH. Clinical course of intestinal Behcet's disease during the first five years. Dig Dis Sci. 2013; 58:496–503. PMID: 22899244.

56. Chung MJ, Cheon JH, Kim SU, et al. Response rates to medical treatments and long-term clinical outcomes of nonsurgical patients with intestinal Behçet disease. J Clin Gastroenterol. 2010; 44:e116–e122. DOI: 10.1097/MCG.0b013e3181c8a50f. PMID: 20054283.

57. Moon CM, Cheon JH, Shin JK, et al. Prediction of free bowel perforation in patients with intestinal Behçet's disease using clinical and colonoscopic findings. Dig Dis Sci. 2010; 55:2904–2911. PMID: 20094787.

58. Iida M, Kobayashi H, Matsumoto T, et al. Postoperative recurrence in patients with intestinal Behçet's disease. Dis Colon Rectum. 1994; 37:16–21. PMID: 8287741.

59. Jung YS, Yoon JY, Lee JH, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet's disease. Inflamm Bowel Dis. 2011; 17:1594–1602. PMID: 21674717.